Anne Brody Rubin
President at Perceive Biotherapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kristen MacFarlane | F | 60 |
Perceive Biotherapeutics, Inc.
 Perceive Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Perceive Biotherapeutics, Inc. is a biotech company that is focused on developing a diverse pipeline of targets and treatment modalities for various therapeutic verticals, with a particular emphasis on ophthalmology. The company is based in South San Francisco, CA. Perceive is backed by Deerfield Management and is planning to raise a series B later this year. The company was founded based on research that identified two novel protective biologies for treating retinal blindness, which were developed from collaborations in genetic science and target validation. Kristen Angela MacFarlane has been the CEO of the company since 2020. | 4 years |
| Debi Watson | F | - |
Perceive Biotherapeutics, Inc.
Perceive Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Perceive Biotherapeutics, Inc. is a biotech company that is focused on developing a diverse pipeline of targets and treatment modalities for various therapeutic verticals, with a particular emphasis on ophthalmology. The company is based in South San Francisco, CA. Perceive is backed by Deerfield Management and is planning to raise a series B later this year. The company was founded based on research that identified two novel protective biologies for treating retinal blindness, which were developed from collaborations in genetic science and target validation. Kristen Angela MacFarlane has been the CEO of the company since 2020. | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Lisa G. Garrett | F | 55 |
ForSight VISION5, Inc.
 ForSight VISION5, Inc. Electronic Equipment/InstrumentsElectronic Technology ForSight VISION5, Inc. develops ocular drug delivery technologies and device solutions for ophthalmic diseases. It engages in the development of non-invasive products to replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. Its lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive their medication. The company was founded by Eugene de Juan Jr., J. Andrew Corley and K. Angela Macfarlane in 2010 and is headquartered in Madison, NJ. | - |
| Hector Casab | M | - |
ForSight VISION5, Inc.
ForSight VISION5, Inc. Electronic Equipment/InstrumentsElectronic Technology ForSight VISION5, Inc. develops ocular drug delivery technologies and device solutions for ophthalmic diseases. It engages in the development of non-invasive products to replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. Its lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive their medication. The company was founded by Eugene de Juan Jr., J. Andrew Corley and K. Angela Macfarlane in 2010 and is headquartered in Madison, NJ. | 1 years |
| Aaron Davidson | M | 55 |
ForSight VISION5, Inc.
ForSight VISION5, Inc. Electronic Equipment/InstrumentsElectronic Technology ForSight VISION5, Inc. develops ocular drug delivery technologies and device solutions for ophthalmic diseases. It engages in the development of non-invasive products to replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. Its lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive their medication. The company was founded by Eugene de Juan Jr., J. Andrew Corley and K. Angela Macfarlane in 2010 and is headquartered in Madison, NJ. | 2 years |
| Charles Semba | M | 64 |
ForSight VISION5, Inc.
ForSight VISION5, Inc. Electronic Equipment/InstrumentsElectronic Technology ForSight VISION5, Inc. develops ocular drug delivery technologies and device solutions for ophthalmic diseases. It engages in the development of non-invasive products to replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. Its lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive their medication. The company was founded by Eugene de Juan Jr., J. Andrew Corley and K. Angela Macfarlane in 2010 and is headquartered in Madison, NJ. | 2 years |
| Carlos A. Schuler | M | - |
ForSight VISION5, Inc.
ForSight VISION5, Inc. Electronic Equipment/InstrumentsElectronic Technology ForSight VISION5, Inc. develops ocular drug delivery technologies and device solutions for ophthalmic diseases. It engages in the development of non-invasive products to replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. Its lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive their medication. The company was founded by Eugene de Juan Jr., J. Andrew Corley and K. Angela Macfarlane in 2010 and is headquartered in Madison, NJ. | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 7 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Anne Brody Rubin
- Personal Network
